<SEC-DOCUMENT>0001022079-16-000246.txt : 20160527
<SEC-HEADER>0001022079-16-000246.hdr.sgml : 20160527
<ACCEPTANCE-DATETIME>20160420162156
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001022079-16-000246
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20160420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUEST DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001022079
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				161387862
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		3 GIRALDA FARMS
		CITY:			MADISON
		STATE:			NJ
		ZIP:			07940
		BUSINESS PHONE:		9735202700

	MAIL ADDRESS:	
		STREET 1:		3 GIRALDA FARMS
		CITY:			MADISON
		STATE:			NJ
		ZIP:			07940

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNING CLINICAL LABORATORIES INC
		DATE OF NAME CHANGE:	19960903
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>CORRESP</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6183133c31e946a3ba8b2dd97cd9c663"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;"><img src="logoa02.gif" style="height:74px;width:216px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Via EDGAR</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Craig Arakawa</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accounting Branch Chief</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Office of Beverages, Apparel and Mining</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Division of Corporation Finance</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">United States Securities and Exchange Commission </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">100 F Street, N.E.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Re: Quest Diagnostics Incorporated</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;Form 10-K for the Fiscal Year Ended December 31, 2015</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;Filed February 26, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;File No. 001-12215</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dear Mr. Arakawa:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">We acknowledge receipt of your letter dated April 7, 2016 to Quest Diagnostics Incorporated (the &#8220;Company&#8221;) regarding the comments of the staff (the &#8220;Staff&#8221;) of the Securities and Exchange Commission (the &#8220;Commission&#8221;) with respect to the Form 10-K filing identified above.  Set forth below is the Company&#8217;s response to the Staff&#8217;s comments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Form 10-K for the Year Ended December 31, 2015 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notes to Consolidated Financial Statements </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">6. Dispositions and Held for Sale </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Dispositions </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Contribution of Clinical Trials Business, page F-20 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1. </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">We note from your disclosure that your contribution of the clinical trials testing business resulted in a pre-tax gain of $334 million based on the difference between the fair value of the Company&#8217;s equity interest in the newly formed joint venture over the carrying value of the assets contributed. You also disclose that you used discounted cash flows to derive the fair value of your equity interest in the joint venture. Please confirm to us that you will expand your disclosure in future filings to describe key assumptions used in your discounted cash flows approach to derive the fair value of your equity interest in the newly formed joint venture. In addition, describe in your disclosure the nature of your continuing involvement with these contributed assets and Q</font><font style="font-family:inherit;font-size:11pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;Solutions and whether a related-party relationship exists. Refer to the disclosure requirements outlined in ASC 810-10-50-1B(d) through (h). Please provide us your proposed disclosures in your response. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Response:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company confirms that it will disclose in future filings the key assumptions used in the discounted cash flows approach to derive the fair value of its equity interest in Q</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Solutions.  In addition, the Company will describe the nature of its continuing involvement with the contributed assets and Q&#178; Solutions and whether a related-party relationship exists.  The Company will include these disclosures in the Company&#8217;s next filing that discusses the Q</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Solutions joint venture transaction, which is expected to be the Company&#8217;s third quarter 2016 Quarterly Report on Form 10-Q.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s6183133c31e946a3ba8b2dd97cd9c663"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company notes that it disclosed in Note 20, Related Parties, in the 10-K filing identified above its related party transactions with its equity method investees, which includes Q</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Solutions.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company&#8217;s proposed future disclosure, with new information underlined, is presented below.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On March 30, 2015, the Company entered into a definitive agreement with Quintiles Transnational Holdings Inc. to form a global clinical trials central laboratory services joint venture, Q</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Solutions.  The transaction closed on July 1, 2015.  In connection with the transaction, the Company contributed certain assets of its clinical trials testing business ("Clinical Trials") and $33 million of cash to the newly formed joint venture in exchange for a non-controlling, 40% ownership interest.  The assets of Clinical Trials contributed to the joint venture, principally consisting of property, plant and equipment and goodwill, were classified as assets held for sale in the first quarter of 2015 and were contributed to Q</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Solutions upon closing of the transaction.  Subsequent to closing, the Company's ownership interest in the joint venture is being accounted for under the equity method of accounting.  At </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">September 30, 2016 and</font><font style="font-family:inherit;font-size:11pt;">&#32;December&#160;31, 2015, the investment in Q</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Solutions had a carrying value of </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">$[X] million and</font><font style="font-family:inherit;font-size:11pt;">&#32;$416 million</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">, respectively</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">During the third quarter of 2015, the Company recognized a pre-tax gain of $334 million based on the difference between the fair value of the Company's equity interest in the newly formed joint venture over the carrying value of the assets contributed.  The fair value of the Company's equity interest was determined using discounted cash flows.  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">The most significant assumptions used in the valuation include a discount rate (12%), a long-term growth rate (2.5%) and EBITDA margins</font><font style="font-family:inherit;font-size:11pt;">.  In connection with the gain, the Company recorded a deferred tax liability of $145 million.  Upon formation, the Company's investment in Q</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Solutions exceeded its equity in the underlying net assets by approximately $219 million.  This basis difference is attributable to finite-lived assets, indefinite-lived intangible assets and goodwill of the joint venture.  The basis difference associated with the finite-lived assets of $75 million is being amortized over a weighted average useful life of 8 years as a reduction to the carrying value of the investment in equity method investees and corresponding reduction in equity in earnings of equity method investees, net of taxes.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Q&#178; Solutions is considered a related party to the Company due to the Company&#8217;s non-controlling ownership interest in Q</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;Solutions and the Company&#8217;s continuing involvement in providing diagnostic information services on an ongoing basis.  In addition, the Company provides transition services to Q&#178; Solutions for a limited period of time.  For further details regarding related parties, see Note [X].  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Clinical Trials, prior to July 1, 2015, is included in all other operating segments and has not been classified as discontinued operations.  For further details regarding business segment information, see Note [X].</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">19. Business Segment Information, page F-41 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;Please revise the notes to your financial statements to disclose the revenues associated with each of your principal services during each period presented in your statements of operations. In this regard, we note from the disclosures on page 11 of your filing that you derived 61% of your revenues from routine clinical testing services, 32% of revenues from gene-based, esoteric and anatomic pathology testing services and 7% from healthcare information technology, clinical trials testing, risk assessment services and diagnostic products during 2015. Refer to the disclosure requirements outlined in ASC 280-10-50-40. Please provide us your proposed disclosures in your response. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Response:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company confirms that it will include in the Company&#8217;s 2016 Annual Report on Form 10-K disclosure (in the Business Segment Information financial statement footnote) regarding the Company&#8217;s net revenues for each major service.  The disclosure will be substantially equivalent to the disclosure set forth in the following table, and will be updated as appropriate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s6183133c31e946a3ba8b2dd97cd9c663"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net revenues by major service were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.57431749241658%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:2%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Routine clinical testing services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;$    4,580 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;$    4,549 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Gene-based and esoteric testing services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,754 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,676 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Anatomic pathology testing services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;631 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;648 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;528 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;562 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Total net revenues</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;$    7,493 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;$    7,435 </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">***</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company acknowledges that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company is responsible for the adequacy and accuracy of the disclosure in its filings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Staff comments, or changes to the Company&#8217;s disclosure in response to Staff comments, do not foreclose the Commission from taking any action with respect to the Company&#8217;s filings; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">If you have any questions regarding the Company&#8217;s response, or you require additional information, please feel free to contact me at 973-520-2173.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Sincerely,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Mark J. Guinan&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mark J. Guinan</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Senior Vice President and Chief Financial Officer</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Cc: Stephen H. Rusckowski, President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;Michael E. Prevoznik, Senior Vice President and General Counsel</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;Robert Treuhold, Shearman &amp; Sterling, LLP</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;Timothy R. Weld, PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logoa02.gif
<TEXT>
begin 644 logoa02.gif
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MBA-(@$ $"23 0)4);<=# @>XR.:5=%*T'2@?HJ@C?B&&B&.)YI38YP#%G&D
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MU!YB $A"4@(0Z10=!9>@!K2LAYFL4</2%LD6N4PAA_L3J2+IQRUF!XGONH_
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MJ!^^#!"!8H2H6FV\*4(J"=)BY I&Z-$= B2PHK\VDDNEHE !ME" "D^XPA(
MYVI(^\ 1!<I/GK4E KPT*E$Y]FKJHZR>OC==2(VI=@QJ[D0$T( F?H2B[9SJ
M1VP6P1!"LR"LT]X6+KK'^F#R(&I<$%$'0 J8TK:J13T14@N"_\CI.;A-"HA
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M4641%JMM8@#%T* YZX,IDG+_<@<?0$(U^+2LH,"KHR-(404*=4"T 1"C3G0
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M^9/YFR 3\.$)H9);P@^/%XWHXMT' 98^8P#:*A^#:N?+F@#9+A__T7XNYY4
M8*4@4])$.JD@A(/6D32I-0*%&BP!G2X0YDU*+<+M=_'"%,&RWY*P'8R1H9R,
M?;3&#'AE'X&#5M.#[<+D':'1<9YI\>&?0A>VJ]*"%9( /# >Z3&07K+NB1H
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M;T$]#LZZ>YNKU*R[30E%FE3EY#+7V<X+9M6$(W#+WX6B21-P5Y.*@23Q$-,
M';YSHA6]:$8WVM&/AG2D)3UI2E?:TI?&=*8UO6E.=]K3GP9UJ$4]:E*7VM2G
M1G6J5;UJ5K?:U5*OAG6L93UK6M?:UK?&=:YUO6M>]]K7OP9VL(4];&(7V]C'
M1G:RE;UL9C?;V<^&=K2E/6UJ5]O:U\9VMK6];6YWV]O?!G>XQ3UN<I?;W.=&
M=[K5*;UN=K?;W>^&=[SE/6]ZU]O>]\9WOO6];W[WV]__!GC !3YP@A=<V0$!
" #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
